F-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth

ARAZ M., Cayir D.

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, cilt.26, sa.1, ss.1-8, 2017 (ESCI) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 26 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/mirt.60783
  • Dergi Adı: MOLECULAR IMAGING AND RADIONUCLIDE THERAPY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1-8
  • Anahtar Kelimeler: Thyroid cancer, positron emission tomography, F-18-fluorodeoxyglucose, HURTHLE CELL-CARCINOMA, METABOLIC TUMOR VOLUME, F-18-FDG PET, PROGNOSTIC VALUE, CLINICAL-SIGNIFICANCE, DIAGNOSTIC-ACCURACY, F-18-DOPA PET/CT, FDG-PET, MANAGEMENT, RECURRENT
  • Ankara Üniversitesi Adresli: Evet

Özet

Positron emission tomography/computed tomography (PET/CT) with F-18-fluorodeoxyglucose (FDG) is used in staging, restaging, and evaluation of therapy response in many cancers as well as differentiated thyroid carcinomas especially in non-iodine avid variants. Its potential in less frequent thyroid tumors like medullary, anaplastic thyroid cancers, thyroid lymphoma and metastatic tumors of the thyroid however, is not well established yet. The aim of this review is to provide an overview on the recent applications and indications of F-18-FDG PET/CT in these tumors and to focus on the controversies in the clinical setting.